Device Firm Earnings: Winners And Losers

In this earnings review, we pick out the high achievers and underperformers from the companies that released quarterly results in the past week. Reports from J&J, ResMed, bioMérieux, St. Jude Medical and more.

Johnson & Johnson (JNJ): Dropping Cordis appears to be working out so far for the massive conglomerate, whose medical device units reported some good news amidst an ongoing restructuring, announced Jan. 16, that will cost about 3,000 jobs. (See [A#01160125002].) Excluding the net impact of acquisitions and divestitures, on an operational basis, Johnson & Johnson’s worldwide medical sales increased 2.5%, domestic sales increased 3.3% and international sales increased 2.0%. Including the impact of divestitures, J&J’s overall 2015 medical devices sales were $25.1 billion for all of 2015, representing an operational revenue decline of 1.4%, driven mainly by a 1.7% operational revenue drop in international markets. During its Jan. 26 earnings call, the company cited strong sales in surgery, orthopedics, electrophysiology and vision care, partially offset by the divestiture of the Cordis business in March. (See Also see "Cardinal Health Builds On Generic Device Strategy With Cordis Deal" - Medtech Insight, 2 March, 2015..)

ResMed Inc. (RMD): The sleep and respiratory device-maker appears to be containing the damage caused by the negative findings...

More from Strategy

Medtronic, Philips Cement New Pact To Embed Next-Gen Tech In Monitoring Platforms

 
• By 

Under the terms of the new agreement, Philips will also begin bundling essential supplies – including ECG, noninvasive blood pressure (NIBP) components, and batteries – with its Medtronic-enabled monitors.

HealthAI: ‘Established Regulations Already Exist For Regulating AI In Healthcare Safely’

 

Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.

Endo Tools, Fujifilm Partner to Fast-Track Endomina Rollout Across MEA Region

 
• By 

CEO Alexandre Chau told Medtech Insight that the Middle East and Africa presented the ideal mix of market potential, physician training opportunities, and regulatory readiness when the company was considering expansion markets beyond Europe and the US.

Thena Capital’s New Fund Up And Running With £1M Investment In Plexāā’s Breast Cancer Device

 

Thena Capital, the first UK-based early-stage specialist medtech firm, has made its first investment since closing its £50m fund. Medtech Insight spoke with general partner Pamela Walker Geddes to gain insight into Thena Capital’s investment strategy.

More from Business

Endo Tools, Fujifilm Partner to Fast-Track Endomina Rollout Across MEA Region

 
• By 

CEO Alexandre Chau told Medtech Insight that the Middle East and Africa presented the ideal mix of market potential, physician training opportunities, and regulatory readiness when the company was considering expansion markets beyond Europe and the US.

FDA Greenlights Expanded Use Of Boston Scientific’s Pulse Field Ablation System

 

A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.

Thena Capital’s New Fund Up And Running With £1M Investment In Plexāā’s Breast Cancer Device

 

Thena Capital, the first UK-based early-stage specialist medtech firm, has made its first investment since closing its £50m fund. Medtech Insight spoke with general partner Pamela Walker Geddes to gain insight into Thena Capital’s investment strategy.